General Information of Drug (ID: DMNTC7O)

Drug Name
RO-4995819 Drug Info
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Phase 2 [1]
Cross-matching ID
PubChem CID
71533696
CAS Number
CAS 911115-16-7
TTD Drug ID
DMNTC7O

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY404039 DMWZIRJ Schizophrenia 6A20 Phase 3 [3]
Oleoyl-estrone DM0RA8F Alzheimer disease 8A20 Phase 2 [4]
MP-101 DMYCITZ Alzheimer disease 8A20 Phase 2 [5]
BCI-838 DMRXDN3 Major depressive disorder 6A70.3 Phase 1 [6]
Pomaglumetad DMTOLI5 Schizophrenia 6A20 Phase 1 [7]
BCI-632 DMZYCWT Alzheimer disease 8A20 Phase 1 [8]
PMID25435285-Compound-16 DMKFX2G N. A. N. A. Patented [9]
PMID25435285-Compound-15 DMHBWNS N. A. N. A. Patented [9]
PMID25435285-Compound-20 DMG9FYH N. A. N. A. Patented [9]
PMID25435285-Compound-22 DM27U1F N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Oleoyl-estrone DM0RA8F Alzheimer disease 8A20 Phase 2 [4]
MP-101 DMYCITZ Alzheimer disease 8A20 Phase 2 [5]
JNJ-64281802 DMNMSVX Dengue 1D20-1D2Z Phase 2 [10]
BCI-838 DMRXDN3 Major depressive disorder 6A70.3 Phase 1 [6]
Pomaglumetad DMTOLI5 Schizophrenia 6A20 Phase 1 [7]
BCI-632 DMZYCWT Alzheimer disease 8A20 Phase 1 [8]
LY-2979165 DM16IX2 Bipolar disorder 6A60 Phase 1 [11]
JNJ-42491293 DMOL9JR Psychiatric disorder 6E8Z Phase 1 [12]
ADX71149 DMBUOX4 Epilepsy 8A60-8A68 Phase 1 [13]
PMID25435285-Compound-16 DMKFX2G N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Metabotropic glutamate receptor 2 (mGluR2) TTXJ47W GRM2_HUMAN Modulator [2]
Metabotropic glutamate receptor 3 (mGluR3) TT8A9EF GRM3_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01457677) ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment in Hoffmann-La Roche.
2 Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
3 Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
6 Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
7 LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
8 Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
9 Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.
10 Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. J Psychopharmacol. 2015 Apr;29(4):414-25.
11 Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78).
12 Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708.
13 MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1).